Previous close | 94.86 |
Open | 104.20 |
Bid | 106.66 x 700 |
Ask | 107.03 x 300 |
Day's range | 100.90 - 110.16 |
52-week range | 43.89 - 110.16 |
Volume | |
Avg. volume | 813,908 |
Market cap | 6.721B |
Beta (5Y monthly) | 0.65 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Detailed Analysis of Financial Performance and Strategic Updates
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 19.51% and 16.40%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.